Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cross Country Healthcare (CCRN) Long-Term Deferred Tax (2017 - 2025)

Cross Country Healthcare (CCRN) has disclosed Long-Term Deferred Tax for 12 consecutive years, with $9.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax changed N/A year-over-year to $9.5 million, compared with a TTM value of $9.5 million through Sep 2025, changed N/A, and an annual FY2024 reading of $8.1 million, up 36.11% over the prior year.
  • Long-Term Deferred Tax was $9.5 million for Q3 2025 at Cross Country Healthcare, up from $8.2 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $11.5 million in Q4 2021 and bottomed at $6.0 million in Q4 2023.
  • Average Long-Term Deferred Tax over 5 years is $8.3 million, with a median of $8.1 million recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax plummeted 38.25% in 2022, then skyrocketed 36.11% in 2024.
  • Year by year, Long-Term Deferred Tax stood at $11.5 million in 2021, then tumbled by 38.25% to $7.1 million in 2022, then decreased by 16.34% to $6.0 million in 2023, then surged by 36.11% to $8.1 million in 2024, then rose by 16.73% to $9.5 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for CCRN at $9.5 million in Q3 2025, $8.2 million in Q2 2025, and $8.8 million in Q1 2025.